News Releases

Keyword Search

Aug-28-2019
Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing
Aug-08-2019
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug-06-2019
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
Aug-01-2019
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
Jun-10-2019
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
Jun-03-2019
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib
May-15-2019
Oncternal to Present Interim Phase 1/2 Cirmtuzumab Data at ASCO
Mar-07-2019
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies
Sep-12-2018
1st Pt Dosed in Phs 1b Clinical Trial of Cirmtuzumab in Combo w/ Paclitaxel in Pts w/ Breast Cancer
Jun-01-2018
Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell